PO-0035Propranolol Administration For Treatment Of Immature Infantile Haemangiomas(iih) In Infants; Any Cardiac Effects?

IntroductionPropranolol is now being used as an alternative to steroid treatment for IIH.Aim of the studyTo evaluate the cardiac effects of propranolol in infancy.MethodsAll patients with IIH between January 2011-December 2013, treated with propranolol, underwent cardiac examination: heart rate (HR), blood pressure (BP), satO2, electrocardiogram and echocardiography (shortening fraction and ejection fraction). Cardiac evaluation was repeated after 1 week, 4 weeks, and then every 6 months.ResultsWe have analysed 42 patients divided into 2 groups: 33 patients (1-6 months, mean weight 6.5 plus or minus 1.3 kg) and 9 patients (6-15 months, mean weight 10.6 plus or minus 2.4 kg). No adverse effects in any patients and none required discontinuation of treatment. In the first group the median HR centile was 50th at baseline, 41thafter 1month and 44th at the end of treatment. In the second group the median HR centile was 43th at baseline, 34th after 1 month and 37th at the end of treatment. In the first group the mean SF was 39% at baseline, 40% and 40% at the end of treatment: the mean EF was respectively 74.5%, 72% and 73%. For the second group the mean SF was 38%, 39% and 39%: the mean EF respectively was 73.1% at baseline, 74% after 1 month and 74.2% at the end of treatment.ConclusionIn our study we have observed signs of rapid involution of hemangioma within the 2-3 first weeks of treatment in all patients. All patients have responded well to treatment, with no side effects and especially no cardiac effect.